Is Sinopharm Weiqida Pharmaceutical Co., Ltd. a state-owned enterprise?

Yes, Sinopharm Weiqida Pharmaceutical Co., Ltd. is a state-owned enterprise.

Sinopharm Weiqida Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company controlled by China National Pharmaceutical Group, and is also an important part of Sinopharm Datong Antibiotics Industrial Base. The company was registered and established in September 2002 and is located in Datong City, Shanxi Province, with a total area of ??650 acres. The company's subsidiary holds Sinopharm Datong Weiqida Zhongbang Pharmaceutical Co., Ltd., which has a complete industrial chain of antibiotic intermediates, APIs, and preparation products and an annual production capacity of 600 tons of potassium clavulanate.

As the core enterprise of Sinopharm Datong Antibiotic Industrial Base, Sinopharm Weiqida Pharmaceutical Co., Ltd. has formed a pharmaceutical industry with cephalosporin antibiotic intermediates 7-ACA, 6-APA, 7-ADCA and Clavil The whole antibiotic industry chain with potassium acid as the core. At the same time, the company has a complete industrial chain from cephalosporin antibiotic intermediate 7-ACA to crude cephalosporin products, cephalosporin sterile powder, cephalosporin powder injection preparations and the largest clavulanate potassium production line in the country. These strong production capabilities and technological advantages give the company an important influence in the global antibiotic industry.

In order to better meet market demand and promote the company's sustainable development, Sinopharm Weiqida Pharmaceutical Co., Ltd. has established product research and development bases in Guangzhou, Shanghai and the company headquarters, forming a comprehensive system from basic research to product development. full-process innovation system. At the same time, the company has established a marketing network covering more than 20 countries and regions around the world, and continues to meet the needs of different countries and regions through market research and continuous optimization of marketing strategies.

According to the strategic development plan of China National Pharmaceutical Group, Sinopharm Weiqida Pharmaceutical Co., Ltd. has completed the construction of a new factory in Datong Pharmaceutical Industrial Park. The new factory has the production capacity of the three major antibiotic cores, 7-ACA, 6-APA, and 7-ADCA, as well as the entire industry chain, which further enhances the company's comprehensive competitiveness. With the continuous development of Sinopharm Datong Antibiotic Industrial Base, more new products and technologies will be released in the future, bringing more good news to patients around the world.

If you need to know more about Sinopharm Weiqida Pharmaceutical Co., Ltd., it is recommended that you go to Qizknow-Free Company Search 》》》》》